Whatsapp
Posted : Thursday, April 18, 2024 07:03 AM
Company Profile:
Vaxcyte, Inc.
(Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).
The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform.
Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella.
The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
For more information, visit www.
vaxcyte.
com.
Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth.
Following equity offerings in October 2022 and April 2023, which generated over $1.
1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24.
These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older.
The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children.
VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions.
Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD.
Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease.
We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.
Summary: Vaxcyte is looking for an energetic and talented individual to join the Drug Product Development (DP) team.
The primary responsibilities for the incumbent will be to support the DP process development of pre-clinical programs through to the phase 3 and commercial readiness.
This position will require the candidate to develop scalable and scaled manufacturing process for Vaxcyte’s vaccine portfolio, being highly complex biological products.
Due to the high number Drug Substances within the DP and a suspended adjuvant system, this is arguably one of the most complex Drug Products in clinical development, so it is an incredible opportunity for the right candidate to make a significant impact on the product, the company, and the industry.
The candidate will need to relish the scope and size of this unique challenge.
In addition, our pre-clinical vaccine program, VAX-A1, is moving into a period of high intensity focus in preparation for GLP and GMP work.
Essential Functions: Develop early-stage DP manufacturing processes including aspects relating to scale-down model development, characterization, and scale-up of unit operations for parenteral manufacturing (i.
e.
filling, filtration, mixing, etc.
).
Enable the team in general process design, including contact material selection, hardware design/construction, filter selection/sizing, mixing and filling activities at the phase 1 scale and in down scaled models.
Aid in oversight of the fill finish CMO service provider to support early, late, and commercial stage manufacturing deliverables and fill/finish process development.
In concert with the CMC team and external guidance, aid in late-stage process characterization and process validation.
Lead all aspects of and engage in the planning, design, execution, and documentation of DP fill/finish process development studies.
Collaborate with the DP Formulation Team to troubleshoot and optimize the DP as required for phase 1, 2, 3 and commercial needs.
Drive continuous improvement in DP development process through technological innovation and application of first principles in process engineering.
Participate in process development activities for commercial drug product manufacturing operations during sterile processing, process characterization, tech transfer, process validation, and ongoing commercial manufacturing.
Apply statistical/data analytics techniques to draw conclusions and make informed decisions.
Requirements: Bachelor’s degree and >6 years of scientific/process development experience OR Master’s degree and >4 years of scientific/process development experience.
BSc or MSc in Chemical Engineering, Pharmaceutical Sciences, the physical sciences, or a related field preferred.
Experience in clinical/commercial manufacturing within fill finish sites and understanding of Quality systems and Drug Product Manufacturing under GMP regulations preferred.
Apply knowledge of pharmaceutical science and engineering to overcome challenges around drug product manufacturing and scale up.
Experience in the development of scaleup/down models for DS or DP processes Strong interpersonal and leadership skills; ability to communicate effectively both verbally and in written formats.
Ability to work within in a fast-paced, cross functional environment, multitasking as needed.
Ability to independently design and implement drug product process development and characterization experiments while adhering to scientifically-sound practices, including the design, execution, review, and interpretation of experiments.
All Vaxcyte employees require vaccination against COVID-19.
Reports to: Senior Engineer, Drug Product Engineering Location: San Carlos, CA Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $124,000 - $138,000 Send resumes to: careers@vaxcyte.
com Vaxcyte, Inc.
825 Industrial Road, Suite 300 San Carlos, CA 94070 We are an equal opportunity employer.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
(Nasdaq: PCVX) is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).
The Company is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and our exclusively licensed XpressCFTM cell-free protein synthesis platform.
Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
Vaxcyte’s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine program designed to prevent Shigella.
The Company is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.
For more information, visit www.
vaxcyte.
com.
Vaxcyte, headquartered in San Carlos, CA, went public in June 2020 and currently has a team of approximately 180 employees and anticipates continued, significant growth.
Following equity offerings in October 2022 and April 2023, which generated over $1.
1 billion in net proceeds, the Company’s balance sheet is further strengthened to advance its pipeline of novel vaccines, including VAX-24.
These financings followed positive data readouts from Vaxcyte’s Phase 1/2 proof-of-concept study evaluating VAX-24 in adults aged 18-64 and Phase 2 study in adults 65 and older.
The Company believes these results support a best-in-class potential for VAX-24, which was designed to replace the current standard-of-care in adults and children.
VAX-24 is being investigated for the prevention of IPD, which can be most serious for infants, young children, older adults and those with immune deficiencies or certain chronic health conditions.
Given the global impact of pneumococcal disease remains significant, the public health community continues to advocate for vaccines that can offer broader protection to prevent IPD.
Vaxcyte’s PCV franchise, consisting of VAX-24 and VAX-31, is designed specifically to address this need and has the potential to deliver the broadest protection for this very serious disease.
We believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies.
Summary: Vaxcyte is looking for an energetic and talented individual to join the Drug Product Development (DP) team.
The primary responsibilities for the incumbent will be to support the DP process development of pre-clinical programs through to the phase 3 and commercial readiness.
This position will require the candidate to develop scalable and scaled manufacturing process for Vaxcyte’s vaccine portfolio, being highly complex biological products.
Due to the high number Drug Substances within the DP and a suspended adjuvant system, this is arguably one of the most complex Drug Products in clinical development, so it is an incredible opportunity for the right candidate to make a significant impact on the product, the company, and the industry.
The candidate will need to relish the scope and size of this unique challenge.
In addition, our pre-clinical vaccine program, VAX-A1, is moving into a period of high intensity focus in preparation for GLP and GMP work.
Essential Functions: Develop early-stage DP manufacturing processes including aspects relating to scale-down model development, characterization, and scale-up of unit operations for parenteral manufacturing (i.
e.
filling, filtration, mixing, etc.
).
Enable the team in general process design, including contact material selection, hardware design/construction, filter selection/sizing, mixing and filling activities at the phase 1 scale and in down scaled models.
Aid in oversight of the fill finish CMO service provider to support early, late, and commercial stage manufacturing deliverables and fill/finish process development.
In concert with the CMC team and external guidance, aid in late-stage process characterization and process validation.
Lead all aspects of and engage in the planning, design, execution, and documentation of DP fill/finish process development studies.
Collaborate with the DP Formulation Team to troubleshoot and optimize the DP as required for phase 1, 2, 3 and commercial needs.
Drive continuous improvement in DP development process through technological innovation and application of first principles in process engineering.
Participate in process development activities for commercial drug product manufacturing operations during sterile processing, process characterization, tech transfer, process validation, and ongoing commercial manufacturing.
Apply statistical/data analytics techniques to draw conclusions and make informed decisions.
Requirements: Bachelor’s degree and >6 years of scientific/process development experience OR Master’s degree and >4 years of scientific/process development experience.
BSc or MSc in Chemical Engineering, Pharmaceutical Sciences, the physical sciences, or a related field preferred.
Experience in clinical/commercial manufacturing within fill finish sites and understanding of Quality systems and Drug Product Manufacturing under GMP regulations preferred.
Apply knowledge of pharmaceutical science and engineering to overcome challenges around drug product manufacturing and scale up.
Experience in the development of scaleup/down models for DS or DP processes Strong interpersonal and leadership skills; ability to communicate effectively both verbally and in written formats.
Ability to work within in a fast-paced, cross functional environment, multitasking as needed.
Ability to independently design and implement drug product process development and characterization experiments while adhering to scientifically-sound practices, including the design, execution, review, and interpretation of experiments.
All Vaxcyte employees require vaccination against COVID-19.
Reports to: Senior Engineer, Drug Product Engineering Location: San Carlos, CA Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component.
Salary Range: $124,000 - $138,000 Send resumes to: careers@vaxcyte.
com Vaxcyte, Inc.
825 Industrial Road, Suite 300 San Carlos, CA 94070 We are an equal opportunity employer.
All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
• Phone : NA
• Location : 825 Industrial Rd Ste 300, San Carlos, CA
• Post ID: 9001165559
